Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV

Clinical Infectious Diseases

Volumn 58, Issue 10, 2014, Pages 1459-1466

  Luo, Ling ^a   Zeng, Yong ^a   Li, Taisheng ^a   Lv, Wei ^a   Wang, Huanling ^a   Guo, Fuping ^a   Han, Yang ^a   Xie, Jing ^a   Qiu, Zhifeng ^a   Li, Yanling ^a   Song, Xiaojing ^a   Zhu, Ting ^a   Zhang, Xiaoying ^a   Li, Ling ^a   Ye, Yicong ^a   He, Yun ^b   Lu, Hongzhou ^c   Huang, Aiqiong ^d   Tang, Xiaoping ^e   Wang, Hui ^f   Zhang, Tong ^g   Gao, Guiju ^h   Lei, Junkang ⁱ   Wu, Xinhua ^j   Sun, Yongtao ^k   Bai, Jinsong ^l   Li, Kunli ^m   more..

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b Department of Infectious Diseases   (China)

^c FUDAN UNIVERSITY   (China)

^d FUJIAN MEDICAL UNIVERSITY   (China)

^e Guangzhou Eighth People's Hospital   (China)

^f SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^g CAPITAL MEDICAL UNIVERSITY   (China)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ Yunnan AIDS Care Center   (China)

^j First People's Hospital of Honghe State   (China)

^k FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^l Third People's Hospital of Kunming   (China)

^m Kunming Third People's Hospital ^*  (China)

more..

Author keywords

ART; Cardiac abnormalities; Echocardiography; HIV

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BODY SURFACE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECG ABNORMALITY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; ADOLESCENT; AGED; CHINA; COMPLICATION; ECHOGRAPHY; HEART DISEASES; HEART LEFT VENTRICLE FUNCTION; HIV INFECTIONS; HYPERTENSION, PULMONARY; MIDDLE AGED; PROSPECTIVE STUDY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHINA; COHORT STUDIES; ECHOCARDIOGRAPHY; HEART DISEASES; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 84899884165     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu086     Document Type: Article

References (38)

1. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adultHIV infection. 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-70.
2. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilatedcardiomyopathy and detection of HIV in myocardial cells of HIVpositivepatients. N Engl J Med 1998; 339:1093-9.
3. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet2000; 356:1423-30.
4. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascularand cerebrovascular events in patients treated for human immunodeficiencyvirus infection. N Engl J Med 2003; 348:702-10.
5. Schuster I, Thöni GJ, Edérhy S, et al. Subclinical cardiac abnormalitiesin human immunodeficiency virus-infected men receiving antiretroviraltherapy. Am J Cardiol 2008; 101:1213-7.
6. Mondy KE, Gottdiener J, Overton ET, et al. SUN Study Investigators.High prevalence of echocardiographic abnormalities among HIVinfectedpersons in the era of highly active antiretroviral therapy. ClinInfect Dis 2011; 52:378-86.
7. Nzuobontane D, Blackett KN, Kuaban C. Cardiac involvement in HIVinfected people in Yaounde, Cameroon. Postgrad Med J 2002; 78:678-81.
8. Martínez-García T, Sobrino JM, Pujol E, Galvez J, Benítez E, Girón-González JA. Ventricular mass and diastolic function in patients infectedby the human immunodeficiency virus. Heart 2000; 84:620-4.
9. Luo L, Ye Y, Liu Z, et al. Assessment of cardiac diastolic dysfunction inHIV-infected people without cardiovascular symptoms in China. Int JSTD AIDS 2010; 21:814-8.
10. Martinez-Garcia T, Sobrino JM, Pujol E, et al. Ventricular mass and diastolicfunction in patients infected by the human immunodeficiencyvirus. Heart 2000; 84:620-4.
11. Li T, Guo F, Li Y, et al. An antiretroviral regimen containing 6 months ofstavudine followed by long-term zidovudine for first-line HIV therapy isoptimal in resource-limited settings: a prospective, multicenter study inChina. Chin Med J (Engl) 2014; 127:59-65.
12. Wang H, Li Y, Zhang C, et al. Immunological and virological responsesto cART in HIV/HBV co-infected patients from a multicenter cohort.AIDS 2012; 26:1755-63.
13. Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension guidelines for the managementof hypertension. Guidelines sub-committee of the WorldHealth Organization. Clin Exp Hypertens 1999; 21:1009-60.
14. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamberquantification. A report from the American Society of Echocardiography'sGuidelines and Standards Committee and the ChamberQuantification Writing Group. J Am Soc Echocardiogr 2004; 18:1440-60.
15. Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is anindependent risk factor for death in patients with sickle cell disease.J Am Coll Cardiol 2007; 49:472-9.
16. Benjamin EJ, Levy D, Anderson KM, et al. Determinants of Dopplerindexes of left ventricular diastolic function in normal subjects (theFramingham Heart Study). Am J Cardiol 1992; 70:508-15?.
17. Munagala VK, Jacobsen SJ, Mahoney DW, et al. Association of newerdiastolic function parameters with age in healthy subjects: a population-based study. J Am Soc Echocardiogr 2003; 16:1049-56.
18. Ommen SR, Nishimura RA, Hurrell DG, Klarich KW. Assessment ofright atrial pressure with 2-dimensional and Doppler echocardiography:a simultaneous catheterization and echocardiographic study. Mayo ClinProc 2000; 75:24-9.
19. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations forevaluation of the severity of native valvular regurgitation with twodimensionaland Doppler echocardiography. J Am Soc Echocardiogr2003; 16:777-802.
20. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIVrelatedpulmonary arterial hypertension in the current antiretroviraltherapy era. Am J Respir Crit Care Med 2008; 177:108-13.
21. Devereux RB, Alonso DR, Lutas EM. Echocardiographic assessmentof left ventricular hypertrophy: comparison to necropsy findings. AmJ Cardiol 1986; 57:450-8.
22. Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-modeechocardiographic left ventricular anatomic measurements. J Am CollCardiol 1984; 4:1222-30.
23. Nunez E, Arnett DK, Benjamin EJ, et al. Optimal threshold value for leftventricular hypertrophy in blacks: the atherosclerosis risk in communitiesstudy. Hypertension 2005; 45:58-63.
24. Mansoor A, Golub ET, Dehovitz J, et al. The association of HIVinfection with left ventricular mass/hypertrophy. AIDS Res HumRetroviruses 2009; 25:475-81.
25. Barbaro G, Lorenzo GD, Grisorio B, et al. Incidence of dilated cardiomyopathyand detection of HIV in myocardial cells of HIV positive patients.N Engl J Med 1998; 339:1093-9.
26. Pozzan G, Pagliari C, Tuon FF, et al. Diffuse-regressive alterations andapoptosis of myocytes: possible causes of myocardial dysfunction inHIV-related cardiomyopathy. Int J Cardiol 2009; 132:90-5.
27. Herskowitz A, Wu TC, Willoughby SB, et al. Myocarditis and cardiotropicviral infection associated with severe left ventricular dysfunctionin late-stage infection with human immunodeficiency virus. J Am CollCardiol 1994; 24:1025-32.
28. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Cardiac involvementin the acquired immunodeficiency syndrome: a multicenter clinicalpathologicalstudy. Gruppo Italiano per lo Studio Cardiologico dei pazientiaffetti da AIDS Investigators. AIDS Res Hum Retroviruses 1998;14:1071-7.
29. Monsuez JJ, Escaut L, Teicher E, Charniot JC, Vittecoq D. Cytokines inHIV-associated cardiomyopathy. Int J Cardiol 2007; 120:150-7.
30. DAD Study GroupFriis-Moller N, Reiss P, et al. Class of antiretroviraldrugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
31. Meng Q, Lima JA, Lai H, et al. Use of HIV protease inhibitors is associatedwith left ventricular morphologic changes and diastolic dysfunction.J Acquir Immune Defic Syndr 2002; 30: 306-10.
32. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovasculardisease in HIV-infected patients and relationship to highlyactive antiretroviral therapy. Circulation 2008; 118:e29-35.
33. Sabin CA, Worm SW. Conventional cardiovascular risk factors in HIVinfection: how conventional are they? Curr Opin HIV AIDS 2008;3:214-9.
34. Erichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrialdamage associated with nucleoside reverse-transcriptase inhibitors.N Engl J Med 2002; 347:1895-6.
35. Tanum J, Ishizaki A, Gatanaga H, et al. Dilated cardiomyopathy in anadult human immunodeficiency virus type 1-positive patient treatedwith a zidovudine-containing antiretroviral regimen. Clin Infect Dis2003; 37:e109-11.
36. Sabin CA, Worm SW, Weber R, et al. D:A:D Study Group. Use ofnucleoside reverse transcriptase inhibitors and risk of myocardial infarctionin HIV-infected patients enrolled in the D:A:D study: amulti-cohort collaboration. Lancet 2008; 371:1417-26.
37. Kitahata MM, Gange SJ, Abraham AA, et al. Effect of early versus deferredantiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-26.
38. Oka F, Naito T, Oike M, et al. Correlation between HIV disease and lipidmetabolism in antiretroviral-naive HIV-infected patients in Japan. J InfectChemother 2012; 18:17-21.